Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Subspecialties

Diagnostics, access, therapies on minds ahead of ASCO

April 2025—Rebecca Previs, MD, MS, gynecologic oncologist and director of medical affairs at Labcorp, captures the vibe ahead of the ASCO conference next month in Chicago in just a few words. “It’s exciting,” she says. “This is unprecedented territory.” With the field undergoing “a major shift toward biology-driven rather than tissue-of-origin-driven oncology treatment,” Dr. Previs is far from the only industry representative who is optimistic about the future—though the many challenges ahead temper that excitement.

Liquid biopsy’s promise and complexities

March 2025—Like an inspired Adam in the Garden of Eden, molecular experts have been busy with the naming process as it applies to liquid biopsy. It’s lost to the myths of time whether Adam revised his nomenclature, but pathologists and other experts are eager to identify new assays as they push this field forward, from circulating cell-free DNA to circulating tumor DNA to circulating tumor RNA. Soon another assay, one that combines ctDNA and ctRNA, could begin to make its mark as well, says Keyur P. Patel, MD, PhD, medical director of the molecular diagnostics laboratory, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center. He and his colleagues plan to launch an assay to look for circulating total nucleic acid. “DNA plus RNA equals TNA—that’s the mathematical equation,” jokes Dr. Patel, who is also professor, Department of Hematopathology, Division of Pathology and Laboratory Medicine. And like that first zookeeper, there’s even an actual beast for experts to name.

Interpreting patient PEth post-transfusion

March 2025—Theresa Kinard, MD, knew little about phosphatidylethanol (PEth), a blood-based biomarker of alcohol use, when she noticed that patients who adamantly denied drinking were testing positive in their liver pretransplant evaluations.

Staining, scoring tips for claudin 18 assay

March 2025—The Ventana CLDN18 (43-14A) RxDx Assay, the companion diagnostic for zolbetuximab, detects the claudin 18 protein in formalin-fixed, paraffin-embedded gastric adenocarcinoma including gastroesophageal junction tissue specimens. Gastric intestinal metaplasia can be used as a positive tissue control and system level control and should display weak to moderate membrane staining.

In clinical path practice, generative AI’s many uses

March 2025—For clinical pathology practice, generative artificial intelligence can open new efficiencies and opportunities, and the authors of an article published in Archives of Pathology & Laboratory Medicine set out how it can be used and its risks.

What oncology patients say about pathology reports

March 2025—A study of oncology patients at the Medical College of Wisconsin sheds light on how they perceive the content and timing of pathology report review. The study findings were gathered through in-person and telehealth interviews with patients with breast, endocrine, gastrointestinal, genitourinary, and thoracic malignancies. Medical student Amber Y. Bo, MD, in 2022 and 2023 conducted 230 interviews with patients who had a prior opportunity to review their reports in the patient portal.

Changes to note in all common, lab general checklists

March 2025—Revised requirements in the 2024 edition of the CAP accreditation all common and laboratory general checklists address the activity menu, alternative performance assessment, the quality management system, and infectious disease reporting, among other things. “When we make revisions in the requirements, we do it for good reason,” says Stephen J. Sarewitz, MD, advisor to and immediate past chair of the CAP Checklists Committee. “In many cases it is to clarify something that was unclear” and raised questions. “In other cases, a change addresses an area in which laboratories get deficiencies, which we are trying to prevent. We also want to reflect state-of-the-art laboratory medicine. As it advances, the checklists are revised accordingly.”

On value, preanalytics, and personnel in urinalysis

March 2025—Urinalysis reflex rules, reimbursement, instruments, research, and specimen handling and transport are some of what came up in the Jan. 15 roundtable with eight participants online and CAP TODAY publisher Bob McGonnagle leading the discussion.

Room to grow: tumor-germline sequencing

February 2025—Genetic profiling has long had proven winners in oncology: somatic testing of tumors, and germline testing for surveillance and to identify potentially affected relatives.

The shift from cotesting to primary HPV screening

February 2025—Eric Huang, MD, PhD, is the first to admit that when it came time to switch to primary HPV testing, his laboratory at the University of Washington faced fewer obstacles than most. Dr. Huang joined the university in 2018 as director of the cytopathology laboratory.

MARKETPLACE

TRENDING